A BILL to amend the Code of Virginia by adding in Article 1 of Chapter 10 of Title 32.1 a section numbered 32.1-331.07, relating to managed care organizations; pharmacy benefits manager; data collection and reporting requirements; civil penalty.
HB1109 would add a new section to the Virginia Code requiring managed care organizations (MCOs) and pharmacy benefits managers (PBMs) involved in medical assistance services to use standardized methods for collecting and reporting drug-related financial and utilization data to the Department of Medical Assistance Services (DMAS) and the Centers for Medicare and Medicaid Services. The required reporting would include detailed information on expenditures, rebates, cost components, drug spending, utilization rates, and prescription volumes, and DMAS would be directed to set the reporting standards by regulation.
The bill also requires public disclosure of transactions tied to drug pricing, PBM-negotiated rebates, and reimbursements, and it would require MCOs to undergo an independent audit of their reporting practices every two years. If audits reveal significant inaccuracies, DMAS could take corrective action. To enforce compliance, the bill would create a DMAS compliance unit with authority to provide guidance and training, require corrective action plans, suspend participation in medical assistance administration for noncompliant entities, and impose civil penalties of up to $10,000, with penalty revenue deposited into the general fund.
If enacted, HB1109 would expand DMAS oversight of Medicaid managed care and PBM reporting by creating new statutory data collection, audit, disclosure, and enforcement requirements. It would affect managed care organizations, pharmacy benefits managers, and pharmacies participating in Virginia’s medical assistance programs by increasing transparency obligations and subjecting them to periodic audits and possible sanctions for inaccurate reporting. The bill would also require DMAS to promulgate regulations and establish a compliance unit, adding administrative responsibilities to the agency and potentially affecting how drug costs and rebate arrangements are tracked and reviewed in state Medicaid operations.
The available record shows no committee transcript or recorded votes, so there is no direct evidence of debate or partisan sentiment in the provided materials. Based on the bill’s structure, it appears aimed at increasing transparency and accountability in drug pricing and Medicaid managed care, which is generally framed as a consumer- and oversight-oriented policy. However, the bill’s placement in Appropriations suggests fiscal and administrative concerns may have been relevant to its consideration.
The main likely points of contention are the scope of required disclosure, the burden of standardized reporting and biennial independent audits, and the enforcement powers granted to DMAS. MCOs and PBMs may object to public disclosure of rebate and reimbursement transactions, as well as to the compliance costs associated with new reporting systems and audits. DMAS and supporters of transparency would likely emphasize the need to verify drug spending and rebate flows, while opponents may focus on administrative complexity, confidentiality concerns, and the possibility of suspension or penalties for reporting deficiencies.